Cargando…
UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2
Germline pathogenic variants (GPVs) in the cancer predisposition genes BRCA1, BRCA2, MLH1, MSH2, MSH6, BRIP1, PALB2, RAD51D and RAD51C are identified in approximately 15% of patients with ovarian cancer (OC). While there are clear guidelines around clinical management of cancer risk in patients with...
Autores principales: | Hanson, Helen, Kulkarni, Anjana, Loong, Lucy, Kavanaugh, Grace, Torr, Bethany, Allen, Sophie, Ahmed, Munaza, Antoniou, Antonis C, Cleaver, Ruth, Dabir, Tabib, Evans, D Gareth, Golightly, Ellen, Jewell, Rosalyn, Kohut, Kelly, Manchanda, Ranjit, Murray, Alex, Murray, Jennie, Ong, Kai-Ren, Rosenthal, Adam N, Woodward, Emma Roisin, Eccles, Diana M, Turnbull, Clare, Tischkowitz, Marc, Lalloo, Fiona |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176381/ https://www.ncbi.nlm.nih.gov/pubmed/36411032 http://dx.doi.org/10.1136/jmg-2022-108898 |
Ejemplares similares
-
Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations
por: Vysotskaia, Valentina, et al.
Publicado: (2019) -
Enhancement of the RAD51 Recombinase Activity by the Tumor Suppressor PALB2
por: Dray, Eloïse, et al.
Publicado: (2010) -
Age of ovarian cancer diagnosis among BRIP1, RAD51C, and RAD51D mutation carriers identified through multi-gene panel testing
por: Cummings, Shelly, et al.
Publicado: (2021) -
Roles of XRCC2, RAD51B and RAD51D in RAD51-Independent SSA Recombination
por: Serra, Heïdi, et al.
Publicado: (2013) -
Structure and function of the RAD51B-RAD51C-RAD51D-XRCC2 tumour suppressor
por: Greenhough, Luke A., et al.
Publicado: (2023)